Business Wire - Research and Markets: Gain an Insight into the Latest Trends and Events Impacting the Pharmaceutical Company - Johnson & Johnson
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c37459) has announced the addition of the Espicom Business Intelligence Ltd report: Johnson & Johnson Pharmaceutical Company Intelligence Report to their offering
Pharmaceutical company intelligence reports provide a full review of the company’s activities together with five-year sales forecasts for its key products. The company’s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company’s product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Related Results
WASHINGTON INSIDER: Update
Levaquin[R] receives FDA approval for treatment of chronic bacterial prostati…
Short-course Levaquin approved.(PRODUCTS)(Brief Article)
FDA grants approval for new oral solution of Levaquin
Pipeline
Summary
Johnson & Johnson’s operating activities are conducted within three business segments: Medical Devices & Diagnostics, Pharmaceutical and Consumer. This report provides a full review of the company’s pharmaceutical activities.
Johnson & Johnson, through more than 230 operating companies, manufactures and sells a broad range of products in the healthcare field for the pharmaceutical, consumer, and medical devices and diagnostic markets to most countries of the world. The company is organised on the principles of decentralised management.
Current Growth Drivers
Within the Pharmaceutical segment in 2005, strong sales performances were demonstrated by Risperdal and Risperdal Consta, Remicade, Topamax and Levaquin.
Key Late-Stage Products
Virology is a relatively new area of focus for J&J and it is currently developing three HIV compounds of which TMC114, the most advanced compound, has been filed. Candidates in Phase III trials include:
Ceftobiprole for complicated skin and skin structure infections and nosocomial pneumonia. Both indications have been granted fast track designation by the FDA.
Doripenem, a broad-spectrum antibiotic for complicated urinary tract infections, complicated intra-abdominal infections and nosocomial pneumonia.
BAY 59-7939 (Factor Xa inhibitor) for venous thromboembolism prevention after major orthopaedic surgery (hip and knee).
This company report provides
Latest Results
A brief review of the latest report results
Executive Summary
At a glance understanding of the major trends and events affecting the company
Financial Analysis (current year)
Detailed P&L and investment review of the latest full year performance
Company Strategy
Where’s the company going and how does it plan getting there?
Product/R&D Pipeline
Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available
Appendices
5-year financial assessment
Key corporate events
Key agreements
Infrastructure
Major pharmaceutical subsidiaries/joint ventures
Product index
Companies Mentioned Include:
- Ablynx - AdipoGenix Inc - Amgen - Arena Pharmaceuticals Inc - Barrier Therapeutics - Basilea Pharmaceutica AG - Bayer - Biovail Corporation International - Cara Therapeutics Inc - Cellzome Inc - Crucell NV - Curis Inc - Eisai - Eli Lilly - Entelos Inc - Ferring Pharmaceuticals Inc - GlaxoSmithKline - GTx Inc - Icagen Inc - ImClone Systems Inc - ImmunoGen Inc - Kyowa Hakko - Medivir AB - Mitsubishi Pharma Corporation - Millennium Pharmaceuticals Inc - Morphosys - Mylan Pharmaceuticals Inc - Neurochem Inc - Paradigm Therapeutics Ltd - Pamgene International BV - Pharmaceutical Product Development Inc (PPD) - Roche/Dade Behring - Sangamo BioSciences Inc - Sepracor Inc - Serono - Shire Pharmaceuticals/Synaptec Inc - Taisho Pharmaceutical Co Ltd - Zeltia Group
For more information visit http://www.researchandmarkets.com/reports/c37459
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
